Blinatumomab<\/b>, sold under the brand name\u00a0Blincyto<\/b>, is a\u00a0biopharmaceutical\u00a0medication used for the treatment of\u00a0Philadelphia chromosome-negative relapsed or refractory\u00a0acute lymphoblastic leukemia.<\/sup>\u00a0It belongs to a class of constructed\u00a0monoclonal antibodies,\u00a0bi-specific T-cell engagers\u00a0(BiTEs), that exert action selectively and direct the human immune system to act against tumor cells.<\/p>\n Blinatumomab was approved for medical use in the United States in December 2014, <\/sup>in Australia in November 2015,<\/sup> in Canada in March 2016,\u00a0<\/sup>and in the European Union in November 2023.<\/sup><\/p>\n BLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014<\/strong><\/p>\n BLINCYTO (blinatumomab) may be accessed in India through a named-patient import process<\/strong>\u00a0with a valid doctor\u2019s prescription, and\u00a0Indian Pharma Network (IPN), New Delhi, assists with compliant sourcing<\/strong>\u00a0and delivery of specialty medicines subject to regulatory approvals.<\/p>\n Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations.<\/strong>\u00a0Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.<\/p>\n IPN having representation in<\/strong>\u00a0Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.<\/p>\n Named-patient import facilitator contact details<\/strong> Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.<\/em><\/p>\n NEWS \/ UPDATES<\/strong><\/p>\n Note:<\/strong><\/em> Blincyto is a prescription only medicine, which is used in treating patients with B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease greater than or equal 0.1% and relapsed or refractory B-cell precursor ALL (Acute Lymphoblastic Leukemia).<\/p>\nIs BLINCYTO (blinatumomab) available in India?<\/h4>\n
How to get BLINCYTO injection delivered in India?<\/h4>\n
Who can help source BLINCYTO injection in India legally?<\/h4>\n
\nCompany Name:<\/strong>\u00a0Indian Pharma Network (IPN)
\nAddress:<\/strong>\u00a060\/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
\nFor sourcing and import coordination of specialty medicines, contact:<\/strong>
\nMr. Tarun:<\/strong>\u00a0+91 9891 296 838
\nMr. Neeraj:<\/strong>\u00a0+91 9811 747 774
\nEmail:\u00a0info@indianpharmanetwork.co.in<\/a><\/strong><\/p>\n\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient. Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Brand Name: BLINCYTO Generic Name: blinatumomab. It is used to treat Acute Lymphoblastic Leukemia.<\/h2>\n